DaxibotulinumtoxinA for injection: A review of the current data. Issue 4 (15th June 2022)

• Record Type: Journal Article
• Authors: Chao, Kevin; Moradi, Amir; Khalifian, Saami
• Other Names: Lain Edward guestEditor.
• Is Part Of: Dermatological reviews. Volume 3:Issue 4(2022)
• Page Start: 221
• Page End: 230
• Publication Date: 2022-06-15
• Subjects: botulinum toxin -- DAXI -- neuromodulator -- rhytids; Dermatology -- Periodicals; Electronic journals; 616.5
• DOI: 10.1002/der2.133
• Languages: English
• ISSNs: 2637-7489

Abstract

Abstract: Products containing botulinum toxin type A (BoNTA) are popular for addressing patients' cosmetic and medical concerns. Current BoNTA products in the market had recommended treatment intervals of 12–16 weeks and require repeat visits to maintain therapeutic efficacy. DaxibotulinumtoxinA (DAXI) for injection is a novel neuromodulator with a unique formulation that may provide longer duration of action than those currently available. Here, we will review the literature on DAXI and provide an overview of the clinical formulation, mechanism of action, pivotal clinical trials, indications, safety profile, adverse events, and immunogenicity. DAXI has the potential to improve the management of both aesthetic and neuromuscular conditions. Long‐term clinical data and further studies are needed to confirm the promising initial clinical data.